odyy: the income statement

MyFinsight

For the year ending 2025-07-31.

Unit: Dollar

Income Statement	2025-07-31
Research and development expense	0
General and administrative expense	1,020,753
Loss from operations	-1,020,753
Gain on sale of product candidates and related assets	0
Impairment of investment in preferred stock of oragenics, inc	0
Loss from change in fair value of oragenics, inc. common stock	-459,417
Interest expense	252,516
Other (expense) income, net	-10,005
Net loss	-1,742,691
Deemed dividend	0
Net loss attributable to common stockholders	-1,742,691

Basic net loss per share attributable to common stockholders	-0.02
Diluted net loss per share attributable to common stockholders	-0.02
Shares used for basic net loss per share attributable to common stockholders	104,709,763
Shares used for diluted net loss per share attributable to common stockholders	104,709,763